Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 17/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | MMP14 | P50281 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP16 | P51512 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762272 | 0.91 | BDKRB1 (0.47) | BDKRB1PPARGCA1CA2MMP2 | |
| SCHEMBL6762632 | 0.89 | BDKRB1 (0.63) | BDKRB1PPARG | |
| SCHEMBL6760011 | 0.86 | BDKRB1 (0.67) | BDKRB1PPARG | |
| SCHEMBL6762616 | 0.86 | BDKRB1 (0.49) | BDKRB1 | |
| SCHEMBL6767110 | 0.82 | BDKRB1 (0.64) | BDKRB1 | |
| SCHEMBL4913323 | 0.79 | BDKRB1 (0.61) | BDKRB1 | |
| SCHEMBL6761725 | 0.79 | BDKRB1 (0.63) | BDKRB1 | |
| SCHEMBL6766732 | 0.78 | BDKRB1 (0.48) | BDKRB1PPARG | |
| SCHEMBL6760053 | 0.78 | BDKRB1 (0.60) | BDKRB1 | |
| SCHEMBL6759974 | 0.78 | BDKRB1 (0.54) | BDKRB1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
| EP-1351928-A2 | NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER S.A. (FR) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002053516-A2 | N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER SA (FR) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | BDKRB1 481/4885PPARG 1475/4885CA1 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.